FIRALIS S.A.

Within Basel neighbourhood and at the very heart of Europe (the triple border of France, Germany and Switzerland), Firalis is a pioneering biotechnology company, active in discovery, development and qualification of biomarkers (BM). 1) BIOMARKER PRODUCTS Firalis develops BM-based diagnostic, prognostic and theranostic tools: ● RUO Kits (Research-Use-Only), based on validated innovative biomarkers ● IVD Tools (In Vitro Diagnostic), based on a combination of clinically qualified biomarkers 2) BIOMARKER R&D ● Development of proprietary BMs - Cardiovascular, Inflammatory, Autoimmune and Neurology ● Drug Safety & Drug Efficacy ● Patient Stratification ● Personalized Medicine 3) BIOMARKER-RELATED CRO SERVICES BM Discovery for laboratories, biotechs and pharmaceutical industry: - Proteomics: Soluble biomarker measurements with several immunoassays technologies (ELISA, multiplex and high sensitivity platforms such as Luminex® BioPlex 200™, Meso Scale Discovery®, Singulex Erenna®, Protein Simple Ella™, Olink and Siemens Dimension® EXL™ 200) - Genomics/Transcriptomics: Targeted sequencing of miRNA and mRNA (HTG EdgeSeq), lncRNA screening via Firalis proprietary platform, Next-Generation Sequencing (NGS) services (RNA-Seq, whole genome and exome sequencing, etc.) and qPCR/microfluidic qPCR (Gene Expression, SNP, CNV, etc.) - Flow Cytometry: Immunophenotyping of preclinical and clinical samples, monitoring of pharmacodynamics on target cells in response to treatment and biomarker discovery - Assay development and validation on various platforms, development of critical reagents (antibodies and proteins) - Biobanking and sample repository services supported by LIMS - Data analysis using multi-parametric statistics and development of predictive models - Support of regulatory activities related to biomarker qualification with Health Authorities (FDA/EMA) - Quality environment (ISO 9001, ISO 13485 (GMP), ISO 17025 (GLP/GCLP)) For more information please visit our website.